Needham & Company LLC Reaffirms “Buy” Rating for Biogen (NASDAQ:BIIB)
Needham & Company LLC reaffirmed their buy rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research note released on Tuesday morning, Benzinga reports. They currently have a $285.00 target price on the biotechnology company’s stock. Several other equities analysts also recently weighed in on BIIB. Barclays lowered their price target on shares […]
More Stories
Insider Selling: Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) CAO Sells 2,352 Shares of Stock
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) CAO Carrie Liao sold 2,352 shares of the firm’s stock in...
ChargePoint Holdings, Inc. (NYSE:CHPT) Insider Sells $18,037.35 in Stock
ChargePoint Holdings, Inc. (NYSE:CHPT – Get Free Report) insider Jagdeep Ca Singh sold 13,361 shares of the business’s stock in...
Kiril Mugerman Purchases 150,000 Shares of Geomega Resources Inc. (CVE:GMA) Stock
Geomega Resources Inc. (CVE:GMA – Get Free Report) Director Kiril Mugerman acquired 150,000 shares of the business’s stock in a...
Analyzing Scinai Immunotherapeutics (NASDAQ:SCNI) & Mesoblast (NASDAQ:MESO)
Mesoblast (NASDAQ:MESO – Get Free Report) and Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) are both small-cap medical companies, but...
Strategic Equity Capital (SEC) to Issue Dividend of GBX 3.50 on November 13th
Strategic Equity Capital (LON:SEC – Get Free Report) announced a dividend on Thursday, September 26th, Upcoming.Co.Uk reports. Shareholders of record...
Sphere 3D Corp. (NASDAQ:ANY) Sees Large Drop in Short Interest
Sphere 3D Corp. (NASDAQ:ANY – Get Free Report) was the target of a large decrease in short interest in September....